RA CAPITAL MANAGEMENT, L.P.
Institutional investor · Portfolio as of Q1 2020
Top Holdings48 positions
Stock | Shares | Value | Weight | Avg Buy | Est. P&L | Held | Conviction |
|---|---|---|---|---|---|---|---|
ASCENDIS PHARMA A/S | 4.9M | $553.5M | 17.5% | $69.04 | +68.02% | 6 qtrssince 2018-Q4 | Increased 72 |
RA PHARMACEUTICALS INC | 4.9M | $233.2M | 7.4% | — | — | 6 qtrssince 2018-Q4 | Unchanged 0 |
| 4.2M | $167.8M | 5.3% | — | — | 2 qtrssince 2019-Q4 | Increased 76 | |
ARVINAS INC | 3.7M | $148M | 4.7% | $29.09 | +41.25% | 6 qtrssince 2018-Q4 | Unchanged 0 |
ZOGENIX INC | 5.3M | $130.5M | 4.1% | — | — | 6 qtrssince 2018-Q4 | Increased 90 |
AXSOME THERAPEUTICS INC | 1.9M | $112M | 3.5% | $49.21 | +17.02% | 5 qtrssince 2019-Q1 | Increased 90 |
EIDOS THERAPEUTICS INC | 2.2M | $105.9M | 3.3% | — | — | 6 qtrssince 2018-Q4 | Unchanged 0 |
TG Therapeutics, Inc. | 10.4M | $102.2M | 3.2% | $6.27 | +64.50% | 6 qtrssince 2018-Q4 | Increased 59 |
SATSUMA PHARMACEUTICALS INC | 4.7M | $100.8M | 3.2% | — | — | 3 qtrssince 2019-Q3 | Unchanged 0 |
ALECTOR INC | 4.1M | $99.6M | 3.1% | $23.10 | +6.06% | 5 qtrssince 2019-Q1 | Increased 90 |
PHATHOM PHARMACEUTICALS INC | 3.7M | $95.7M | 3.0% | $32.39 | -20.16% | 2 qtrssince 2019-Q4 | Increased 57 |
KALA BIO, Inc. | 10.9M | $95.6M | 3.0% | — | — | — | — |
RHYTHM PHARMACEUTICALS INC | 5.4M | $82.5M | 2.6% | $23.88 | -39.27% | 6 qtrssince 2018-Q4 | Unchanged 0 |
89BIO INC | 3.2M | $79.8M | 2.5% | — | — | 2 qtrssince 2019-Q4 | Unchanged 0 |
EXELIXIS INC | 4.5M | $77.9M | 2.5% | $17.77 | +194.43% | 1 qtr | New 78 |
WAVE LIFE SCIENCES LTD | 7.8M | $72.9M | 2.3% | $42.17 | -78.19% | 6 qtrssince 2018-Q4 | Unchanged 0 |
ADVERUM BIOTECHNOLOGIES INC | 7.3M | $71.1M | 2.2% | — | — | — | — |
MOMENTA PHARMACEUTICALS INC | 2.5M | $68.9M | 2.2% | — | — | 2 qtrssince 2019-Q4 | Increased 78 |
BLACK DIAMOND THERAPEUTICS I | 2.6M | $64.6M | 2.0% | $25.40 | 0.00% | 1 qtr | New 77 |
| 4.2M | $60.8M | 1.9% | — | — | — | Decreased 0 |
RA CAPITAL MANAGEMENT, L.P. manages $3.2B across 48 positions as of Q1 2020. Top holdings: ASND (17.5%), RARX (7.4%), CHEMOCENTRYX INC (5.3%). Fund DNA: Balanced Allocator. HoldingsIntel Rating: 3/5.0.
Active quarter - 18 new positions, 4 exits, 15 increased. Top move: ZGNX (INCREASED, conviction 90). Portfolio: $3.2B across 48 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer